258 related articles for article (PubMed ID: 12162758)
1. Clinical pharmacokinetics of cytarabine formulations.
Hamada A; Kawaguchi T; Nakano M
Clin Pharmacokinet; 2002; 41(10):705-18. PubMed ID: 12162758
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.
Angst MS; Drover DR
Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
Phuphanich S; Maria B; Braeckman R; Chamberlain M
J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075
[TBL] [Abstract][Full Text] [Related]
4. [The pharmacokinetic study on cytarabine nanoparticle lyophilization injection in rabbits].
Zhou J; Jiang XH; He L; Li CR; Yang JY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):145-7. PubMed ID: 16468665
[TBL] [Abstract][Full Text] [Related]
5. [Rationale for the use of liposomal cytarabine in meningeal carcinomatosis].
Boiardi A
Tumori; 2007; 93(3):suppl 1-3. PubMed ID: 17679478
[No Abstract] [Full Text] [Related]
6. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium.
Bleyer WA
Clin Cancer Res; 1999 Nov; 5(11):3349-51. PubMed ID: 10589743
[No Abstract] [Full Text] [Related]
7. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
Schwendener R; Schott H
Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of encapsulated sustained-release cytarabine.
Murry DJ; Blaney SM
Ann Pharmacother; 2000 Oct; 34(10):1173-8. PubMed ID: 11054987
[TBL] [Abstract][Full Text] [Related]
9. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.
Rueda Domínguez A; Olmos Hidalgo D; Viciana Garrido R; Torres Sánchez E
Clin Transl Oncol; 2005 Jul; 7(6):232-8. PubMed ID: 16131445
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.
Donnette M; Solas C; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Hau LTT; Costello R; Ouafik L; Lacarelle B; Ciccolini J; Fanciullino R
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121770. PubMed ID: 31454720
[TBL] [Abstract][Full Text] [Related]
11. Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
Braess J; Kern W; Unterhalt M; Kaufmann CC; Ramsauer B; Schüssler M; Kaeser-Fröhlich A; Hiddemann W; Schleyer E
Ann Hematol; 1996 Oct; 73(4):201-4. PubMed ID: 8890711
[TBL] [Abstract][Full Text] [Related]
12. [Intrathecal chemotherapy treatment of neoplastic meningitis from solid tumors using liposomal cytarabine: experience at the Istituto Regina Elena di Roma].
Pace A
Tumori; 2007; 93(3):suppl 9-12. PubMed ID: 17679481
[No Abstract] [Full Text] [Related]
13. Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies.
Ueda T; Matsuyama S; Yamauchi T; Kishi S; Fukushima T; Tsutani H; Nakamura T; Gotoh N; Masada M
Adv Exp Med Biol; 1998; 431():647-51. PubMed ID: 9598145
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
Burk M; Heyll A; Arning M; Volmer M; Fartash K; Schneider W
Leuk Lymphoma; 1997 Oct; 27(3-4):321-7. PubMed ID: 9402329
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
Esteva FJ; Soh LT; Holmes FA; Plunkett W; Meyers CA; Forman AD; Hortobagyi GN
Cancer Chemother Pharmacol; 2000; 46(5):382-6. PubMed ID: 11127942
[TBL] [Abstract][Full Text] [Related]
17. The freeze-thawed and freeze-dried stability of cytarabine-encapsulated multivesicular liposomes.
Chen C; Han D; Zhang Y; Yuan Y; Tang X
Int J Pharm; 2010 Mar; 387(1-2):147-53. PubMed ID: 20005932
[TBL] [Abstract][Full Text] [Related]
18. Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples.
Abbara C; Drevin G; Férec S; Ghamrawi S; Souchet S; Robin JB; Schmidt A; Hunault-Berger M; Guardiola P; Briet M
Cancer Chemother Pharmacol; 2020 Nov; 86(5):687-691. PubMed ID: 32990804
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.
Glantz MJ; LaFollette S; Jaeckle KA; Shapiro W; Swinnen L; Rozental JR; Phuphanich S; Rogers LR; Gutheil JC; Batchelor T; Lyter D; Chamberlain M; Maria BL; Schiffer C; Bashir R; Thomas D; Cowens W; Howell SB
J Clin Oncol; 1999 Oct; 17(10):3110-6. PubMed ID: 10506606
[TBL] [Abstract][Full Text] [Related]
20. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy.
Kim S; Kim DJ; Geyer MA; Howell SB
Cancer Res; 1987 Aug; 47(15):3935-7. PubMed ID: 3607740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
